Valuation: Inotiv, Inc.

Market Cap 387K 336K 312K 288K 543K 36.97M 552K 3.7M 1.45M 18.36M 1.45M 1.42M 61.75M P/E 2024
-0.41x
P/E 2025 -0.69x
Enterprise Value 438M 380M 353M 326M 614M 41.81B 625M 4.18B 1.64B 20.76B 1.64B 1.61B 69.83B EV / Sales 2024
0.95x
EV / Sales 2025 0.95x
Free-Float
93.32%
Yield 2024 *
-
Yield 2025 -
1 day-26.00%
Current month+7.77%
1 month+0.91%
3 months-96.41%
6 months-97.84%
Current year-98.03%
1 month 0.01
Extreme 0.01
0.03
Current year 0.01
Extreme 0.007
0.65
1 year 0.01
Extreme 0.007
2.33
3 years 0.01
Extreme 0.007
11.42
5 years 0.01
Extreme 0.007
60.66
10 years 0.01
Extreme 0.007
60.66
Manager TitleAgeSince
Chief Executive Officer 67 12/01/2019
Director of Finance/CFO 61 06/03/2020
Chief Operating Officer 60 15/02/2021
Date Insider Type Main position Quantity % Market Cap.
19/7/26 Others

Chief Executive Officer

-1,361,215 3.9017%
19/7/26 Others

Director

-729,626 2.0913%
19/7/26 Others

Chief Financial Officer

-139,616 0.4002%
Change 5-day change 1-year change 3-year change Capi.($)
-26.00%0.00%-99.45%-99.85% 387K
-0.80%+6.30%-1.72%+13.00% 48.95B
-3.95%+14.70%+24.15%+6.27% 40.75B
+6.22%+1.81%+419.17%+632.08% 38.46B
-1.57%-1.44%+7.38%+50.35% 36.38B
+5.56%+11.70%+11.64%+51.50% 28.45B
-0.39%-0.63% - - 16.62B
-1.13%-4.54%+32.10%+128.42% 16.33B
-7.10%-2.81%-8.80%-34.16% 13.65B
-0.06%-2.81%+3.16%+10.08% 13.56B
Average -2.84%+1.62%+43.07%+84.19% 25.31B
Weighted average by Cap. +0.23%+7.20%+76.39%+127.97%

Financials

2024 2025
Net sales 491M 426M 396M 365M 688M 46.85B 700M 4.69B 1.83B 23.27B 1.84B 1.8B 78.25B 513M 446M 414M 382M 719M 48.98B 732M 4.9B 1.92B 24.32B 1.93B 1.88B 81.8B
Net income -108M -94.2M -87.47M -80.67M -152M -10.35B -155M -1.04B -405M -5.14B -407M -398M -17.29B -68.62M -59.61M -55.35M -51.05M -96.16M -6.55B -97.9M -655M -257M -3.25B -258M -252M -10.94B
Net Debt 424M 368M 342M 315M 594M 40.45B 604M 4.05B 1.58B 20.09B 1.59B 1.56B 67.56B 438M 380M 353M 325M 613M 41.77B 624M 4.18B 1.64B 20.75B 1.64B 1.61B 69.77B
Logo Inotiv, Inc.
Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
Employees
1,996
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. NOTVQ Stock